Stakeholders Urge ‘Carrot and Stick’ Approach to Boost Subgroup Research

Drug Industry Daily
Advocates for minorities and other patient groups that are underrepresented in clinical trials want the FDA to create incentives for drugmakers that include those groups in studies and become more aggressive in delaying drugs that don’t include them.

To View This Article:


Subscribe To Drug Industry Daily